BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19052692)

  • 1. Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy.
    Colagrande M; Di Ianni M; Coletti G; Peris K; Fargnoli MC; Moretti L; Lapecorella M; Tabilio A
    Int J Hematol; 2009 Jan; 89(1):76-79. PubMed ID: 19052692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenalidomide Induced Toxic Epidermal Necrolysis and Del (5q): Co-occurrence of Rarities.
    Chaudhry QUN; Iftikhar R; Satti TM; Mahmood SK; Khan MA; Shahbaz N
    J Coll Physicians Surg Pak; 2018 Jun; 28(6):S89-S90. PubMed ID: 29866231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia.
    Arora B; Mesa R; Tefferi A
    Leuk Lymphoma; 2004 Dec; 45(12):2373-86. PubMed ID: 15621750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thalidomide-induced toxic epidermal necrolysis.
    Horowitz SB; Stirling AL
    Pharmacotherapy; 1999 Oct; 19(10):1177-80. PubMed ID: 10512068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis.
    Wei XQ; Zheng ZH; Jin Y; Tao J; Abassa KK; Wen ZF; Shao CK; Wei HB; Wu B
    World J Gastroenterol; 2014 Sep; 20(33):11921-6. PubMed ID: 25206301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances in thalidomide therapy for idiopathic myelofibrosis].
    Song L; Chen JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):651-3. PubMed ID: 19968089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
    Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
    Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
    Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
    Haematologica; 2001 Jul; 86(7):772-3. PubMed ID: 11454539
    [No Abstract]   [Full Text] [Related]  

  • 9. Steven's Johnson syndrome with toxic epidermal necrolysis due to thalidomide in a case of multiple myeloma.
    Das A; Sil A; Mishra V; Das NK
    Indian J Pharmacol; 2014; 46(5):557-9. PubMed ID: 25298592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide therapy for myelofibrosis with myeloid metaplasia.
    Thomas DA; Giles FJ; Albitar M; Cortes JE; Verstovsek S; Faderl S; O'Brien SM; Garcia-Manero G; Keating MJ; Pierce S; Zeldis J; Kantarjian HM
    Cancer; 2006 May; 106(9):1974-84. PubMed ID: 16583431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
    Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
    Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thalidomide and lenalidomide in primary myelofibrosis.
    Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
    Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide treatment in myelofibrosis with myeloid metaplasia.
    Elliott MA; Mesa RA; Li CY; Hook CC; Ansell SM; Levitt RM; Geyer SM; Tefferi A
    Br J Haematol; 2002 May; 117(2):288-96. PubMed ID: 11972510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
    Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
    Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
    Wäsch R; Jakob T; Technau K; Finke J; Engelhardt M
    Ann Hematol; 2012 Feb; 91(2):287-9. PubMed ID: 21494796
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic epidermal necrolysis due to voriconazole: case report and review.
    Gomulka J; Wilson BD; Joyce JC
    Dermatol Online J; 2014 Sep; 20(9):. PubMed ID: 25244163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Splenic irradiation as a component of a reduced-intensity conditioning regimen for hematopoietic stem cell transplantation in myelofibrosis with massive splenomegaly.
    Ito T; Akagi K; Kondo T; Kawabata H; Ichinohe T; Takaori-Kondo A
    Tohoku J Exp Med; 2012 Dec; 228(4):295-9. PubMed ID: 23117264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
    Tefferi A
    Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mini-dose of thalidomide for treatment of primary myelofibrosis. Report of a case with complete reversal of bone marrow fibrosis and splenomegaly.
    Berrebi A; Feldberg E; Spivak I; Shvidel L
    Haematologica; 2007 Feb; 92(2):e15-6. PubMed ID: 17405746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.